Diabetes and the heart -the battle is not lost yet! After previous cooperative issues in 2008, 2010, 2012, and 2014 , our fifth interdisciplinary edition of Herz/Cardiovascular Diseases dedicated to the topic of the heart and diabetes testifies to the sustainability of the ever-changing problem. In past issues we developed a comprehensive picture of the evolving problems and outlined the given strategies in the routine care process. The joint guidelines of the ESC and the EASD [1] represent a landmark trial to integrate the various components within one algorithm dedicated to improve outcomes rather than surrogate measures of metabolism or vasculature, such as HbA1c or patency rates of coronary blood vessels. However, based on recent epidemiological data, the disease burden is augmented by the recognition of linked comorbidities, such as kidney or brain injury, requiring support by the respective specialities. The remaining residual risk led us to tease the problem with the resigning statement: no reason to stop the warning.
The difficulty to cope with risk identification and appropriate intervention on a population level is addressed by Noel Barengo and Jaako Tuomilehto.
Peter Grant's contribution summarizes the recent pathophysiological findings and Carsten Israel opens a new Pandora's Box highlighting sudden cardiac death as the bottom end of the clinical problem as a composite of atherothrombosis, cardiomyopathy and rhythm instability.
Complementary, Alessandra DeiCas develops a comprehensive overview of heart failure in diabetes mellitus starting from the metabolism driven cardiomyopathy to new therapeutic options in addition to early metabolic control.
After These trials compared a certain antidiabetic agent to placebo aiming for glycaemic equipoise and showed CV safety of the respective drugs (the primary aim of these studies), but could not demonstrate a CV benefit. Good news came from the EMPA-REG Outcome trial [10] , which documented for the first time a significant survival benefit for the SGLT2 inhibitor empagliflozin versus placebo in a high-risk population of patients with type 2 diabetes, opening new perspectives for the therapy of these patients. Here, we are reassured with a robust outcome improvement not knowing what efficacy component drives the clinical benefit. Most probably, metabolic and volume control act together synergistically. Guntram Schernthaner provides us with an updated review of our oral possibilities with the challenging perspective beyond metformin.
Down the line with the guideline goals for lipids, particularly LDL-cholesterol, which at present appears as the predominantdenominatorofvascularhealthfrom an epidemiological point of view, the introduction of the new principle of PCSK9 inhibition could turn out to be a novel tool for target-value achievement, particularly in the population of patients with diabetes and coronary artery disease. Klaus Parhofer discusses the recent data from the RCTs with the available antibody-based components.
The everlasting challenge of finding the best strategy to treat patients with manifest, complex multi-vessel coronary artery disease by means of interventions is addressed by Stephan Windecker with the guideline mandate to define a role for catheter-based interventions versus surgery after the FREEDOM trial [11] .
Altogether, the problem with a growing number of clinical manifestations remains with a steep increase in the number of individuals affected by diabetes and coronary disease conditions and related comorbidities, such as kidney or neurological deficits. However, consequent development of drugs addressing the pathophysiology and clinical research for documenting mode and strength of clinical interventions allows for a smoother clinical judgement -the battle appears not to be lost yet! 
